Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2025
Spring on the Road
Spring Wellness 2025
Canada Votes 2025
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
Auction 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sarepta Therapeutics, Inc. - Common Stock
(NQ:
SRPT
)
60.44
-1.32 (-2.14%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 25, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sarepta Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
19
20
Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
April 25, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Sarepta Therapeutics to Announce First Quarter 2025 Financial Results
April 22, 2025
From
Sarepta Therapeutics, Inc.
Via
Business Wire
SRPT Investors Have Opportunity to Join Sarepta Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
April 21, 2025
From
The Schall Law Firm
Via
Business Wire
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost
April 21, 2025
The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly.
Via
Investor's Business Daily
Topics
Government
Exposures
Political
Product Safety
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
April 21, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Netflix To Rally More Than 55%? Here Are 10 Top Analyst Forecasts For Monday
April 21, 2025
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
April 18, 2025
Via
Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
April 17, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks
April 16, 2025
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with AbbVie...
Via
StockStory
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Sarepta Therapeutics Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs
April 15, 2025
From
Sarepta Therapeutics, Inc.
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
April 12, 2025
From
Pomerantz LLP
Via
GlobeNewswire
SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
April 11, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Fraud
Exposures
Legal
SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
April 11, 2025
RADNOR, PA - April 11, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf...
Via
TheNewswire.com
Topics
Fraud
Exposures
Legal
NASDAQ: SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
April 09, 2025
From
Kessler Topaz Meltzer & Check, LLP
Via
Business Wire
NASDAQ: SRPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
April 08, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Fraud
Exposures
Legal
NASDAQ: SRPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
April 08, 2025
RADNOR, PA - April 8, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of...
Via
TheNewswire.com
Topics
Fraud
Exposures
Legal
Can Solid Biosciences Challenge Sarepta in the DMD Market?
April 08, 2025
Solid Biosciences' Duchenne muscular dystrophy (DMD) drug could provide superior outcomes compared to an already approved medication projected to make billions.
Via
MarketBeat
3 Reasons to Avoid SRPT and 1 Stock to Buy Instead
April 08, 2025
The past six months haven’t been great for Sarepta Therapeutics. It just made a new 52-week low of $52, and shareholders have lost 56.6% of their capital. This may have investors wondering how to...
Via
StockStory
Topics
Supply Chain
Exposures
Supply Chain
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
April 07, 2025
From
Pomerantz LLP
Via
GlobeNewswire
4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street
April 07, 2025
Via
The Motley Fool
Sarepta Therapeutics Temporarily Halts Three Clinical Studies Of Elevidys: Retail Is Dull While Stock Drops
April 04, 2025
H.C. Wainwright told investors in a research note that the clinical hold on key Elevidys trials in Europe heightens the uncertainty around the future of the franchise.
Via
Stocktwits
Topics
Government
Exposures
Political
Sarepta Therapeutics Provides Update on ELEVIDYS
April 04, 2025
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death
April 03, 2025
Sarepta and Roche paused Elevidys trials in the EU after a patient death. Analysts warn of potential sales declines as safety concerns impact market outlook.
Via
Benzinga
Apple To $250? Here Are 10 Top Analyst Forecasts For Thursday
April 03, 2025
Via
Benzinga
Sarepta Plunges After EMA Puts Gene Therapy Studies On Hold Following Teen's Death
April 03, 2025
The holds are temporary while the teenager's death is under investigation.
Via
Investor's Business Daily
Topics
Death
Exposures
Death
Deep Dive Into Sarepta Therapeutics Stock: Analyst Perspectives (18 Ratings)
April 03, 2025
Via
Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
April 03, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Q4 Earnings Outperformers: Amgen (NASDAQ:AMGN) And The Rest Of The Therapeutics Stocks
April 03, 2025
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with Amgen...
Via
StockStory
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
This Charles Schwab Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
April 02, 2025
Via
Benzinga
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 31, 2025
From
Sarepta Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
19
20
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.